KRAS and rectal cancer: We assessed the efficacy of KRAS inhibitors in rectal cancer cell lines, patient‐derived organoids (PDOs), and patient‐derived cell lines (PDCLs), and explored adaptive resistance mechanisms through transcriptomic profiling and unbiased drug screening experiments.